



Diagnostics Biotech Company

NASDAQ: PRPO

Founded in 2011

HQ: New Haven, CT

DISCLAIMER

THIS PRESENTATION HAS BEEN PREPARED BY PRECIPPIO INC. (THE "COMPANY") AND IS GENERAL BACKGROUND INFORMATION ABOUT THE COMPANY'S ACTIVITIES AS OF THE DATE OF THIS PRESENTATION. BY ACCEPTING THIS PRESENTATION, THE RECIPIENT ACKNOWLEDGES AND AGREES THAT ALL OF THE INFORMATION CONTAINED HEREIN IS CONFIDENTIAL, THAT THE RECIPIENT WILL DISTRIBUTE, DISCLOSE, AND USE SUCH INFORMATION ONLY FOR SUCH PURPOSE AND THAT THE RECIPIENT SHALL NOT DISTRIBUTE, DISCLOSE OR USE SUCH INFORMATION IN ANY WAY DETRIMENTAL TO THE COMPANY. THE INFORMATION CONTAINED HEREIN DOES NOT PURPORT TO BE ALL INCLUSIVE AND THE COMPANY NOR ANY OF ITS RESPECTIVE AFFILIATES NOR ANY OF ITS OR THEIR CONTROLLING PERSONS, OFFICERS, DIRECTORS, EMPLOYEES OR REPRESENTATIVES MAKES ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, COMPLETENESS OR RELIABILITY OF THE INFORMATION CONTAINED IN THIS PRESENTATION. THIS PRESENTATION DOES NOT CONTAIN ALL THE INFORMATION THAT IS OR MAY BE MATERIAL TO INVESTORS OR POTENTIAL INVESTORS AND SHOULD NOT BE CONSIDERED AS ADVICE OR A RECOMMENDATION TO INVESTORS OR POTENTIAL INVESTORS IN RESPECT OF THE HOLDING, PURCHASING OR SELLING OF SECURITIES OR OTHER FINANCIAL INSTRUMENTS AND DOES NOT TAKE INTO ACCOUNT ANY INVESTOR'S PARTICULAR OBJECTIVES, FINANCIAL SITUATION OR NEEDS. CERTAIN STATEMENTS IN THIS PRESENTATION MAY CONSTITUTE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 27A OF THE SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, WHICH INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS THAT MAY CAUSE ACTUAL RESULTS TO BE MATERIALLY DIFFERENT FROM ANY ANTICIPATED/FORECASTED RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED OR IMPLIED BY SUCH STATEMENTS. FORWARD-LOOKING STATEMENTS INCLUDE, BUT ARE NOT LIMITED TO, THOSE WITH RESPECT TO MANAGEMENT'S CURRENT VIEWS AND ESTIMATES OF FUTURE ECONOMIC CIRCUMSTANCES, INDUSTRY CONDITIONS, COMPANY PERFORMANCE, FINANCIAL RESULTS, INCLUDING THE ABILITY OF THE COMPANY TO INCREASE ITS PRESENCE/IMPACT/MARKET SHARE IN THE DIAGNOSTIC PRODUCTS AND SERVICES MARKETS, AND REGULATORY MATTERS. THESE FORWARD-LOOKING STATEMENTS ARE BASED UPON ESTIMATES AND ASSUMPTIONS THAT, WHILE CONSIDERED REASONABLE BY THE COMPANY AND ITS MANAGEMENT, AS THE CASE MAY BE, ARE INHERENTLY UNCERTAIN. NEW RISKS AND UNCERTAINTIES MAY EMERGE FROM TIME TO TIME, AND IT IS NOT POSSIBLE TO PREDICT ALL RISKS AND UNCERTAINTIES. THE KNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS AFFECTING THESE FORWARD-LOOKING STATEMENTS ARE DESCRIBED FROM TIME TO TIME IN THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-Q AND 10-K. ANY CHANGE IN SUCH FACTORS, RISKS AND UNCERTAINTIES MAY CAUSE THE ACTUAL RESULTS, EVENTS AND PERFORMANCE TO DIFFER MATERIALLY FROM THOSE REFERRED TO IN SUCH STATEMENTS. FACTORS THAT MAY CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM CURRENT EXPECTATIONS INCLUDE, BUT ARE NOT LIMITED TO, VARIOUS FACTORS BEYOND MANAGEMENT'S CONTROL INCLUDING GENERAL ECONOMIC CONDITIONS AND OTHER RISKS, AS WELL AS FACTORS ASSOCIATED WITH COMPANIES, SUCH AS PRECIPPIO, THAT ARE ENGAGED IN DIAGNOSTICS AND OTHER RESEARCH AND DEVELOPMENT ACTIVITIES IN THE BIOTECHNOLOGY INDUSTRY, INCLUDING UNCERTAINTY IN PRODUCT ACCEPTANCE AND/OR RECEIPT OF REGULATORY APPROVALS FOR PRODUCT CANDIDATES, INCLUDING ANY DELAYS AND OTHER IMPACTS FROM THE COVID 19 PANDEMIC. ACCORDINGLY, THE COMPANY CLAIMS THE PROTECTION OF THE SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS CONTAINED IN THE SECURITIES ACT WITH RESPECT TO ALL STATEMENTS CONTAINED IN THIS PRESENTATION. ALL INFORMATION IN THIS PRESENTATION IS AS OF THE DATE WHEN THIS PRESENTATION WAS PROVIDED TO THE RECIPIENT BY PRECIPPIO AND PRECIPPIO DOES NOT UNDERTAKE ANY DUTY TO UPDATE THIS INFORMATION, INCLUDING ANY FORWARD-LOOKING STATEMENTS, UNLESS REQUIRED BY LAW. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IS MADE AS TO THE FAIRNESS, ACCURACY OR COMPLETENESS OF THE PRESENTATION AND THE INFORMATION CONTAINED HEREIN AND NO RELIANCE SHOULD BE PLACED ON IT. INFORMATION IN THIS PRESENTATION (INCLUDING MARKET DATA AND STATISTICAL INFORMATION) HAS BEEN OBTAINED FROM VARIOUS SOURCES (INCLUDING THIRD-PARTY SOURCES) AND THE COMPANY DOES NOT GUARANTEE THE ACCURACY OR COMPLETENESS OF SUCH INFORMATION, WHILE THE COMPANY BELIEVES ITS INTERNAL RESEARCH IS RELIABLE, SUCH RESEARCH HAS NOT BEEN VERIFIED BY ANY INDEPENDENT SOURCE. ALL PROJECTIONS, VALUATIONS AND STATISTICAL ANALYSES ARE PROVIDED FOR INFORMATION PURPOSES ONLY. THE CONTENTS OF THIS PRESENTATION SHOULD NOT BE CONSIDERED TO BE LEGAL, TAX, INVESTMENT OR OTHER ADVICE, AND ANY INVESTOR OR PROSPECTIVE INVESTOR CONSIDERING THE PURCHASE OR DISPOSAL OF ANY SECURITIES OF THE COMPANY SHOULD CONSULT WITH ITS OWN COUNSEL AND ADVISERS AS TO ALL LEGAL, TAX, REGULATORY, FINANCIAL AND RELATED MATTERS CONCERNING AN INVESTMENT IN OR DISPOSAL OF SUCH SECURITIES AND AS TO THEIR SUITABILITY FOR SUCH INVESTOR OR PROSPECTIVE INVESTOR THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND PROPRIETARY TO THE COMPANY, AND NO PART OF IT OR ITS SUBJECT MATTER MAY BE REPRODUCED, REDISTRIBUTED, PASSED ON, OR THE CONTENTS OTHERWISE DIVULGED, DIRECTLY OR INDIRECTLY, TO ANY OTHER PERSON (EXCLUDING THE RELEVANT PERSON'S PROFESSIONAL ADVISERS) OR PUBLISHED IN WHOLE OR IN PART FOR ANY PURPOSE WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY.



Precipio milestones 2025

+30%


Revenue growth

+275%

Share price increase

Profitable


As of Q3-25





We develop products that save lives

Acute Myeloid Leukemia (AML) is one of the deadliest forms of cancer. Physicians treating patients with AML face two unsuitable options.



Precipio's assay enables immediate, targeted treatment - **SAVING LIVES**



Precipio is eliminating ineffective diagnosis

We eliminate both **misdiagnosis** and **diagnostic delays**, where outcomes depend on speed and accuracy.

25-40%*

of blood cancer diagnoses
are incorrect

10+ Days

generally accepted turnaround
times in molecular testing

\$100B**

diagnostic errors cost US
healthcare annually




* [Journal of Clinical Oncology: Errors in Cancer Diagnosis. June 2007](#)

[American Society of Clinical Oncology: Second-opinion pathologic review. July 2014](#)

** [American Medical Association: Diagnostic error in medicine. Nov 2009](#)




We've built an innovative product development platform, creating an **unfair advantage**






Our profitable clinical lab business fully funds R&D, significantly de-risking the company



Product Release






Example:
Precipio's
BCR-ABL1
assay

1. Most advanced assay in market
2. Development time: 3 months
3. Development cost: <\$100K



We deliver testing options not available before

















Our products address the key challenges laboratories face: Staff shortage, Capital budgets, and the ability to deliver timely results

Factor	Competition	Precipio Solution	Impact
 Workflow	Complex	Simple	Simplified workflow enables streamlined process, fewer errors, and faster results
Labor Skill	High	Low	Lower labor costs; Easier recruiting, training and management of lab staff;
 Capital Equipment	> \$1,000,000	< \$25,000	Lower economic adoption threshold
Gross Margins	10–15%	> 50%	Attractive, contributing economics
 Results Delivery	1–3 weeks	1–3 days	Better patient care



We scale through national distribution partner agreements already in place

Go-to-market efficiency through leading channel partners, with nationwide reach


	POL*	Hospital / Academic	Reference Lab
			
			
			
			

* Physician-Owned Laboratory



Blood cancers are just the beginning: Expanding into a \$40B+ market

Our technology is platform-ready to expand beyond hematology into broader cancer and molecular testing.



* Transparency Market Research Onco-Hematology Molecular Market Testing June 2023


** BioSpace Molecular Diagnostic Market Size Report Aug 2024




Recurring revenue growth, high-margin outlook

As we scale products and alter the revenue mix, gross margins increase dramatically.

Revenue mix



Gross Margin Analysis






Where the Products business can go

Gradual increase in market share, alongside expansion into new fields of diagnostics can deliver significant growth

Market penetration ■ Blood cancers
■ Cancer genetics
■ Molecular diagnostics



Market potential (\$B)

Segment	TAM
Blood cancers	\$ 0.5
Cancer Genetics	\$ 6.7
Molecular Diagnostics	\$ 43.0

Revenue outlook (\$M)

Segment	Current	Short term	Long term
Blood cancers	\$ 5	\$ 25	\$ 125
Cancer Genetics	\$ -	\$ 134	\$ 335
Molecular Diagnostics	\$ -	\$ -	\$ 860




Proven leadership with deep clinical and commercial experience



Ilan Danieli
CEO 



Dr. Ayman Mohamed
CTO 



Zaki Sabet
COO 



Stephen Miller
CCO 



Miri Radomski
CPO & Legal
Counsel 




Matt Gage
CFO 



Precipio: A high-margin, proprietary diagnostics platform with massive upside

- 1 Disruptive, Proprietary Products Rooted in solutions to real-world diagnostic and monitoring challenges
- 2 Unique Development Platform - rapid and capital efficient
- 3 Massive Market Opportunity – growing from \$0.5B TAM to multi billion-dollar markets in the future
- 4 Scalable, cost-efficient Go-To-Market with broad coverage distribution model
- 5 Attractive Business Model – recurring, high margin revenues and a Cash Flow positive business





Thank you.

Please contact us at investors@precipiodx.com